Keywords
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Keywords » - entrée « Antirheumatic Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antirheumatic Agents (administration & dosage) < Antirheumatic Agents (adverse effects) < Antirheumatic Agents (blood)  Facettes :

List of bibliographic references indexed by Antirheumatic Agents (adverse effects)

Number of relevant bibliographic references: 317.
[50-70] [0 - 20][0 - 50][70-90]
Ident.Authors (with country if any)Title
001335 (2018) Kazuha Kizaki [Japon] ; Fumiharu Yamashita [Japon] ; Tomoya Hayashi [Japon] ; Noboru Funakoshi [Japon]Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
001382 (2018) Expanded table: some biologic agents and JAK inhibitors for RA.
001385 (2018) Y. Mansour [France] ; A. Lambert [France] ; M. Tebacher-Alt [France] ; J L Pasquali [France] ; D. Lipsker [France]Eruptive nevi under tocilizumab: first case report and data analysis.
001394 (2018) Jun Kikuchi [Japon] ; Tsuneo Kondo [Japon] ; Akiko Shibata [Japon] ; Ryota Sakai [Japon] ; Yusuke Okada [Japon] ; Kentaro Chino [Japon] ; Ayumi Okuyama [Japon] ; Takahiko Kurasawa [Japon] ; Hirofumi Takei [Japon] ; Koichi Amano [Japon]Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis.
001397 (2018) Osamu Saiki [Japon] ; Hiroshi Uda [Japon]Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
001407 (2018) Mahmoud Abu-Shakra [Israël] ; Devy Zisman [Israël] ; Alexandra Balbir-Gurman [Israël] ; Howard Amital [Israël] ; Yair Levy [Israël] ; Pnina Langevitz [Israël] ; Moshe Tishler [Israël] ; Yair Molad [Israël] ; Suhail Aamar [Israël] ; Itzhak Roser [Israël] ; Nina Avshovich [Israël] ; Daphna Paran [Israël] ; Tatiana Reitblat [Israël] ; Reuven Mader ; Hillel Savin [Israël] ; Joshua Friedman [Israël] ; Nicky Lieberman [Israël] ; Sharon Ehrlich [Israël]Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis.
001408 (2018) Grant S. Schulert [États-Unis] ; Francesca Minoia [Italie] ; John Bohnsack ; Randy Q. Cron ; Soah Hashad [Libye] ; Isabelle Koné-Paut [France] ; Mikhail Kostik [Russie] ; Daniel Lovell [États-Unis] ; Despoina Maritsi [Grèce] ; Peter A. Nigrovic [États-Unis] ; Priyankar Pal [Inde] ; Angelo Ravelli [Italie] ; Masaki Shimizu [Japon] ; Valda Stanevicha [Lettonie] ; Sebastiaan Vastert [Pays-Bas] ; Andreas Woerner [Suisse] ; Fabrizio De Benedetti [Italie] ; Alexei A. Grom [États-Unis]Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
001412 (2018) Drugs for rheumatoid arthritis.
001414 (2018) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Akira Ohnishi [Japon] ; Daijiro Kabata [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Shuzo Yoshida [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Kengo Akashi [Japon] ; Takanori Fujimura [Japon] ; Makoto Hirao [Japon] ; Keiichi Yamamoto [Japon] ; Ayumi Shintani [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
001415 (2018) Der-Yuan Chen [Taïwan] ; Chak Sing Lau [Hong Kong] ; Bassel Elzorkany [Égypte] ; Ping-Ning Hsu [Taïwan] ; Sonja Praprotnik [Slovénie] ; Radu Vasilescu [Belgique] ; Lisa Marshall [États-Unis] ; Lyndon Llamado [Philippines]Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
001431 (2018) Yuki Shono [Japon] ; Masahiro Kamata [Japon] ; Shintaro Takeoka [Japon] ; Tetsuya Ikawa [Japon] ; Mihoko Tateishi [Japon] ; Saki Fukaya [Japon] ; Kotaro Hayashi [Japon] ; Atsuko Fukuyasu [Japon] ; Takamitsu Tanaka [Japon] ; Takeko Ishikawa [Japon] ; Takamitsu Ohnishi [Japon] ; Kurumi Asako [Japon] ; Hajime Kono [Japon] ; Yayoi Tada [Japon]Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab.
001473 (2018) Rossella Talotta [Italie] ; Fabiola Atzeni [Italie] ; Alberto Batticciotto [Italie] ; Maurizio Benucci [Italie] ; Sara Bongiovanni [Italie] ; Piercarlo Sarzi-Puttini [Italie]Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance.
001475 (2018) Rahul Sehgal [États-Unis] ; Erik J. Stratman [États-Unis] ; Jonathan E. Cutlan [États-Unis]Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.
001510 (2018) Graeme Jones [Australie] ; Stephen Hall [Australie] ; Paul Bird [Australie] ; Geoff Littlejohn [Australie] ; Kathleen Tymms [Australie] ; Peter Youssef [Australie] ; Eric Chung [Australie] ; Rina Barrett [Australie] ; Peter Button [Australie]A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
001511 (2018) Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon]A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
001550 (2017) Suqing Xu [République populaire de Chine] ; Xi Xie [République populaire de Chine] ; Mengshi Tang [République populaire de Chine] ; Jinwei Chen [République populaire de Chine] ; Jing Tian [République populaire de Chine] ; Jinfeng Du [République populaire de Chine] ; Ni Mao [République populaire de Chine] ; Yiming Liu [République populaire de Chine] ; Shu Li [République populaire de Chine] ; Meiyan Song [République populaire de Chine] ; Jiesheng Gao [République populaire de Chine] ; Guanghui Ling [République populaire de Chine] ; Fen Li [République populaire de Chine][Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis].
001578 (2017) Yukiko Terada [Japon] ; Koju Kamoi ; Kyoko Ohno-Matsui ; Kazunori Miyata ; Chinami Yamano ; Ariella Coler-Reilly ; Yoshihisa YamanoTreatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.
001582 (2017) Ernest H. Choy [Royaume-Uni] ; Corrado Bernasconi [Suisse] ; Maher Aassi [Suisse] ; Jose Fernando Molina [Colombie] ; Oscar Massimiliano Epis [Italie]Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
001586 (2017) Mark C. Genovese [États-Unis] ; Joel M. Kremer [États-Unis] ; Ronald F. Van Vollenhoven [Pays-Bas] ; Rieke Alten [Allemagne] ; Juan Jose Scali [Argentine] ; Ariella Kelman [États-Unis] ; Sophie Dimonaco [Royaume-Uni] ; Laura Brockwell [Royaume-Uni]Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
001591 (2017) Tatsuhiko Mori [Japon] ; Toshiyuki Yamamoto [Japon]Tocilizumab-induced pustular drug eruption.
001620 (2017) Monika Stensen [Norvège]The use of biologics in pregnant patients with rheumatic disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antirheumatic Agents (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antirheumatic Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antirheumatic Agents (adverse effects)
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021